GlassScriptPhysician profile
Charles C Barr
NPI 1770518409
$3,845.22
in general payments reported to CMS, 2019-2025
19 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $141 · 2021: $657 · 2022: $640 · 2023: $733 · 2024: $493 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $654.13 | 2021-2025 | Eylea Hd, Eylea |
| Regeneron Healthcare Solutions, INC. | $604.52 | 2019-2023 | Eylea Hd |
| Alcon Vision LLC | $502.67 | 2019-2024 | Clareon, Simbrinza, Rhopressa |
| Genentech USA, INC. | $441.04 | 2022-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $220.84 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $180.18 | 2019-2020 | |
| Allergan, INC. | $151.93 | 2019-2020 | |
| Alimera Sciences, INC. | $151.02 | 2019-2024 | Iluvien, Yutiq |
| Glaukos Corporation | $141.68 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $124.74 | 2021 | |
| Aerie Pharmaceuticals, INC. | $122.47 | 2019 | |
| Genentech, INC. | $122.38 | 2021 | |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Eyepoint US, INC. | $109.64 | 2021 | |
| Abbvie INC. | $76.15 | 2023-2025 | Ozurdex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $44.56 | 2019 | |
| Mallinckrodt Hospital Products INC. | $39.47 | 2025 | Acthar |
| Harrow Eye, LLC | $23.31 | 2025 | Iheezo |
| Bausch & Lomb Americas INC. | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.